Dopamine
Partial Agonists (Wiki)
A new class
of antipsychotic, research into Dopamine Partial
Agonists is progressing rapidly and is looking very
promising. More often than not, Dopamine Partial
Agonists are labelled as atypical antipsychotics.
Aripiprazole
(Wiki)
Brand names:
Abilify®
Formula: C23H27Cl2N3O2
Half life: ~ 75 hours
Single unit dose: 3mg per day
Recommended outpatient dose: 15mg per day
[Verified]
Maximum outpatient dose: 30mg per day
[Verified]
The most recent
approved antipsychotic drug (at time of writing),
aripiprazole is being heralded as a wonder
drug. It appears to be more guarunteed to
demonstrate positive results than other
atypical antipsychotics
and is generally well
tolerated. Its stimulant effect also makes it useful in
the treatment of melancholic disorders; on top of this, aripiprazole seems to have a solid
antidepressant effect as well.
Unfortunately, as with any medication, aripiprazole does have downsides. The most
prevelant of these is a particular side effect, namely unwanted movement which can
included teeth chattering, restless legs and so on.
The stimulant effect can meddle in ones sleep and
can cause fatigue after prolonged actiovity.
Finally, Aripiprazole was, on 20th November 2007, approved
for use in addition with antidepressants in combatting depression.
Asenapine
(Wiki)
Brand names:
None known
Formula: C17H16ClNO
Half life: ~ Unknown
Single unit dose: Unknown
Recommended outpatient dose: 10mg per day
[Highly
Questionable]
Maximum outpatient dose: Unknown
The only thing
that I know about this drug is that it is also effective in
combating clinical depression. It is still under
development.
Bifeprunox
(Wiki)
Brand names:
None known
Formula: C25H26ClN3O5S
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown
This
drug is still under development and is
intended to be released in 2007. Its mode of action is
slightly different to the original atypical antipsychotic drugs and is comparable to the
drug aripiprazole of the same family. Trials have shown
bifeprunox to be extremely well tolerated, exhibiting
no weight gain side effects or impacact on blood sugar levels. Of
all four atypical antipsychotics
currently under
developments, this drug is anticipated to be the most
successful, both clinically and financially.
Mosapramine
(Wiki)
Brand
names: None known
Formula: C28H35ClN4O
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown
Mosapramine is a potent Dopamine antagonist with a high affinity
for D2, D3 and D4 receptors but a low affinity for
5-HT2 receptors.
Norclozapine
(Wiki)
Brand names:
None known
Formula: Unknown
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown
No current data.